BCPT Nordic Prize 2024 till Marja-Liisa Dahl

Styrelsen i SFBKF är glad och stolt över att kunna gratulera vår ordförande, Marja-Liisa Dahl, för att ha blivit tilldelat BCPT Nordic Prize 2024. Priset delas ut årligen av tidningen Basic and Clinical Pharmacology and Toxicology. Stort grattis, Marja-Liisa!

Nedan följer motiveringen för priset:

We are happy to announce that the 2024 BCPT Nordic Prize winner is Marja-Liisa Dahl, born in Turku, Finland. She is a renowned clinical pharmacologist with a distinguished academic career. She completed her medical and PhD studies in Finland and Sweden, specializing in drug metabolism, clinical pharmacokinetics and pharmacogenetics of psychotropic drugs. Dr Dahl's research has focused on the impact of genetic variation on drug metabolism and the clinical usefulness of genotyping and plasma drug concentration analysis for individualized drug treatment. She has authored numerous articles and book chapters and has supervised several PhD students. Another more recent research interest includes doping in society and the use of evidence-based knowledge databases on drug interactions and risk factors for pharmacodynamic adverse effects.

She has authored more than 200 original articles and review articles, 50 book chapters and reports. According to Scopus, she has over 14 000 citations, and her Hindex is 70 (11 March 2024). Dr Dahl has extensive experience teaching medical students and healthcare personnel and is leading clinical pharmacology education at Karolinska Institute. Throughout her career, she has integrated research, teaching and clinical work, believing this is essential for developing the discipline.

Dr Dahl is the head of the Department of Clinical Pharmacology at Karolinska University Hospital, overseeing a team of over 140 employees. The department provides clinical pharmacology services, including therapeutic drug monitoring and genotyping. Dahl has also held leadership positions in various national and international organizations, including being appointed chairperson of the Swedish Society for Basic and Clinical Pharmacology. In conclusion, Marja-Liisa Dahl is a highly respected clinical pharmacologist with a strong research, education and clinical practice background. Her scientific discoveries have significantly impacted therapy, and she plays a key role in clinical pharmacology in the Nordic countries. We are happy to honour Dr Dahl with the BCPT Nordic Prize.